Follow
Christoph Röllig
Christoph Röllig
Consultant Hematologist, Universitätsklinikum TU Dresden, Germany
Verified email at uniklinikum-dresden.de - Homepage
Title
Cited by
Cited by
Year
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
14952015
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
H Döhner, AH Wei, FR Appelbaum, C Craddock, CD DiNardo, H Dombret, ...
Blood, The Journal of the American Society of Hematology 140 (12), 1345-1377, 2022
9752022
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ...
The Lancet Oncology 18 (8), 1061-1075, 2017
5002017
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 …
C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ...
The lancet oncology 16 (16), 1691-1699, 2015
4422015
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ...
Leukemia 26 (3), 381-389, 2012
4382012
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation …
A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ...
Journal of Clinical Oncology 38 (26), 2993-3002, 2020
3872020
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the …
U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ...
Journal of Clinical Oncology 35 (6), 605-612, 2017
3872017
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
U Krug, C Röllig, A Koschmieder, A Heinecke, MC Sauerland, M Schaich, ...
The Lancet 376 (9757), 2000-2008, 2010
3482010
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label …
PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ...
The Lancet Oncology 20 (6), 781-794, 2019
3472019
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A Ehninger, M Kramer, C Röllig, C Thiede, M Bornhäuser, M Von Bonin, ...
Blood cancer journal 4 (6), e218-e218, 2014
3332014
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting …
C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, ...
Journal of clinical oncology 29 (20), 2758-2765, 2011
3142011
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 …
U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ...
The Lancet Oncology 19 (12), 1668-1679, 2018
2802018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ...
The Lancet 393 (10168), 253-264, 2019
2412019
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
C Röllig, C Thiede, M Gramatzki, W Aulitzky, H Bodenstein, M Bornhäuser, ...
Blood, The Journal of the American Society of Hematology 116 (6), 971-978, 2010
2282010
How I treat hyperleukocytosis in acute myeloid leukemia
C Röllig, G Ehninger
Blood, The Journal of the American Society of Hematology 125 (21), 3246-3252, 2015
2162015
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
N Shayegi, M Kramer, M Bornhäuser, M Schaich, J Schetelig, ...
Blood, The Journal of the American Society of Hematology 122 (1), 83-92, 2013
2122013
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
MA Dimopoulos, A Palumbo, P Corradini, M Cavo, M Delforge, ...
Blood, The Journal of the American Society of Hematology 128 (4), 497-503, 2016
1692016
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients
M Bornhäuser, C Thiede, U Platzbecker, A Jenke, A Helwig, R Plettig, ...
Clinical cancer research 7 (8), 2254-2262, 2001
1352001
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective …
M Schaich, C Röllig, S Soucek, M Kramer, C Thiede, B Mohr, ...
Journal of clinical oncology 29 (19), 2696-2702, 2011
1332011
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
F Stölzel, C Röllig, J Radke, B Mohr, U Platzbecker, M Bornhäuser, ...
Haematologica 96 (10), 1552, 2011
1252011
The system can't perform the operation now. Try again later.
Articles 1–20